Patents by Inventor Paul Howley

Paul Howley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified vaccinia ankara virus variant
    Patent number: 6761893
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: July 13, 2004
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Modified vaccinia ankara virus variant
    Publication number: 20030215466
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Application
    Filed: May 16, 2003
    Publication date: November 20, 2003
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Modified vaccinia ankara virus variant
    Publication number: 20030206926
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. 1 TABLE 1 CEF Hela HaCat 143B BHK Vero CV-1 MVA- 579.73 0.04 0.22 0.00 65.88 2.33 0.00 BN MVA- 796.53 0.15 1.17 0.02 131.22 10.66 0.06 575 MVA- 86.68 124.97 59.09 0.83 87.86 34.97 29.70 HLR MVA- 251.89 27.41 1.28 2.91 702.77 1416.46 4.
    Type: Application
    Filed: May 16, 2003
    Publication date: November 6, 2003
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
  • Modified vaccinia ankara virus variant
    Publication number: 20030202988
    Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
    Type: Application
    Filed: May 16, 2003
    Publication date: October 30, 2003
    Inventors: Paul Chaplin, Paul Howley, Christine Meisinger